Frequency and Prognosis of JAK2 V617F, Calr, MPL and ASXL1 Mutations in Primary Myelofibrosis

被引：0
|
作者：
Sorigue, Marc [1 ]
Cabezon, Marta [2 ]
Garcia, Olga [1 ]
Velez, Patricia [3 ]
Marce, Silvia [2 ]
Boque, Concha [3 ]
Xicoy, Blanca [1 ]
Fernandez, Cristalina [4 ]
Xandri, Marisol [2 ]
Casanova, Enric [3 ]
Gallardo, David [4 ]
Milla, Fuensanta [2 ]
Ribera, Josep-Maria [2 ]
Feliu, Evarist [2 ]
Zamora, Lurdes [2 ]
机构：
[1] Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, ICO, Josep Carreras Leukemia Res Inst, Badalona, Spain
[2] Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, ICO Badalona, Josep Carreras Leukemia Res Inst, Badalona, Spain
[3] Hosp Duran y Reynals, ICO, Lhospitalet De Llobregat, Spain
[4] Hosp Josep Trueta, ICO, Girona, Spain
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
    Mikic, Tanja Belcic
    Pajic, Tadej
    Sever, Matjaz
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [22] Prevalence of the JAK2 V617F and MPL Mutations in Stroke, Abdominal and Peripheral Venous Thrombosis
    McCarthy, Niamh
    McCarron, Sarah L.
    Langabeer, Stephen E.
    ACTA HAEMATOLOGICA, 2010, 124 (03) : 160 - 161
  • [23] JAK2 V617F, MPL, and CALR Mutations in Essential Thrombocythaemia and Major Thrombotic Complications: A Single-Institute Retrospective Analysis
    Posfai, Eva
    Marton, Imelda
    Kiraly, Peter Attila
    Kotosz, Balazs
    Kiss-Laszlo, Zsuzsanna
    Szell, Marta
    Borbenyi, Zita
    PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (03) : 751 - 758
  • [24] Comparative thrombotic risk associated with CALR1, CALR2, and JAK2 V617F mutations in essential thrombocythemia
    Neupane, Niraj
    Low, Soon K.
    Kharel, Himal
    Bhattarai, Sanket
    Thapa, Sangharsha
    Mahmoud, Amir
    Pokhrel, Nishant B.
    Din, Mohammad Ammad Ud
    Kouides, Peter
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (01) : E26 - E28
  • [25] Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F
    Shide, K.
    Shimoda, H. K.
    Kumano, T.
    Karube, K.
    Kameda, T.
    Takenaka, K.
    Oku, S.
    Abe, H.
    Katayose, K. S.
    Kubuki, Y.
    Kusumoto, K.
    Hasuike, S.
    Tahara, Y.
    Nagata, K.
    Matsuda, T.
    Ohshima, K.
    Harada, M.
    Shimoda, K.
    LEUKEMIA, 2008, 22 (01) : 87 - 95
  • [26] Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F
    K Shide
    H K Shimoda
    T Kumano
    K Karube
    T Kameda
    K Takenaka
    S Oku
    H Abe
    K S Katayose
    Y Kubuki
    K Kusumoto
    S Hasuike
    Y Tahara
    K Nagata
    T Matsuda
    K Ohshima
    M Harada
    K Shimoda
    Leukemia, 2008, 22 : 87 - 95
  • [27] JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis
    Barosi, Giovanni
    Poletto, Valentina
    Massa, Margherita
    Campanelli, Rita
    Villani, Laura
    Bonetti, Elisa
    Viarengo, Gianluca
    Catarsi, Paolo
    Klersy, Catherine
    Rosti, Vittorio
    PLOS ONE, 2013, 8 (03):
  • [28] STUDY OF MYELOFIBROSIS USING JAK2 V617F EXPRESSING MACROPHAGES
    Silyutina, Anna
    Gin, Irina
    Prikhodko, Stanislava
    Butylin, Pavel
    Zaritskey, Andrey
    EXPERIMENTAL HEMATOLOGY, 2017, 53 : S65 - S65
  • [29] V617F mutations of the JAK2 gene in hematological neoplasms
    Mori, N.
    Yoshinaga, K.
    Tada, M.
    Wang, Y-H.
    Shiseki, M.
    Motoji, T.
    EXPERIMENTAL HEMATOLOGY, 2006, 34 (09) : 81 - 81
  • [30] 2 DIFFERENT PHENOTYPES IN ESSENTIAL THROMBOCYTHEMIA: MUTATION JAK2 V617F OR CALR
    Vilches Moreno, A. S.
    Guerrero Fernandez, L.
    Latorre Gonzalez, A.
    Monteagudo Saiz, D.
    Robles Marina, V
    Andreu Costa, A.
    Ayala Diaz, R.
    Martinez Lopez, J.
    HAEMATOLOGICA, 2016, 101 : 187 - 187
12345